Congress Park Capital LLC Heron Therapeutics, Inc. Transaction History

Congress Park Capital LLC

  • $260 Million
  • Q1 2025

A detailed history of Congress Park Capital LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Congress Park Capital LLC holds 2,035,617 shares of HRTX stock, worth $3.87 Million. This represents 1.72% of its overall portfolio holdings.

Number of Shares
2,035,617
Previous 2,455,495 17.1%
Holding current value
$3.87 Million
Previous $3.76 Million 19.22%
% of portfolio
1.72%
Previous 1.38%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 21, 2025
SELL
$1.47 - $2.55 $617,220 - $1.07 Million
-419,878 Reduced 17.1%
2,035,617 $4.48 Million
Q4 2024

Jan 14, 2025
BUY
$1.06 - $2.12 $506,062 - $1.01 Million
477,417 Added 24.14%
2,455,495 $3.76 Million
Q3 2024

Oct 09, 2024
BUY
$1.73 - $3.67 $691,268 - $1.47 Million
399,577 Added 25.31%
1,978,078 $3.94 Million
Q2 2024

Jul 12, 2024
SELL
$2.32 - $3.86 $153,778 - $255,856
-66,284 Reduced 4.03%
1,578,501 $5.52 Million
Q1 2024

Apr 15, 2024
SELL
$1.71 - $3.06 $263,109 - $470,826
-153,865 Reduced 8.55%
1,644,785 $4.56 Million
Q4 2023

Jan 19, 2024
BUY
$0.54 - $1.82 $653,130 - $2.2 Million
1,209,500 Added 205.3%
1,798,650 $3.06 Million
Q3 2023

Oct 13, 2023
BUY
$0.97 - $1.8 $75,563 - $140,220
77,900 Added 15.24%
589,150 $606,000
Q2 2023

Jul 13, 2023
BUY
$1.11 - $2.88 $211,554 - $548,899
190,590 Added 59.44%
511,250 $593,000
Q1 2023

Apr 19, 2023
BUY
$1.51 - $3.25 $91,430 - $196,787
60,550 Added 23.28%
320,660 $484,000
Q4 2022

Jan 27, 2023
BUY
$2.25 - $4.67 $201,037 - $417,264
89,350 Added 52.32%
260,110 $650,000
Q3 2022

Oct 18, 2022
BUY
$2.66 - $5.37 $27,930 - $56,385
10,500 Added 6.55%
170,760 $721,000
Q2 2022

Jul 22, 2022
BUY
$2.3 - $6.29 $74,777 - $204,500
32,512 Added 25.45%
160,260 $447,000
Q1 2022

May 02, 2022
BUY
$4.63 - $9.94 $176,546 - $379,022
38,131 Added 42.55%
127,748 $731,000
Q4 2021

Feb 09, 2022
SELL
$8.35 - $12.6 $251,418 - $379,386
-30,110 Reduced 25.15%
89,617 $818,000
Q3 2021

Nov 03, 2021
SELL
$10.13 - $15.0 $777,578 - $1.15 Million
-76,760 Reduced 39.07%
119,727 $1.28 Million
Q2 2021

Aug 13, 2021
BUY
$13.27 - $18.48 $50,956 - $70,963
3,840 Added 1.99%
196,487 $3.05 Million
Q1 2021

Apr 19, 2021
SELL
$14.49 - $20.72 $72,015 - $102,978
-4,970 Reduced 2.51%
192,647 $3.12 Million
Q4 2020

Jan 19, 2021
SELL
$14.61 - $22.14 $105,659 - $160,116
-7,232 Reduced 3.53%
197,617 $4.18 Million
Q3 2020

Oct 20, 2020
BUY
$13.67 - $17.77 $61,309 - $79,698
4,485 Added 2.24%
204,849 $3.04 Million
Q2 2020

Jul 27, 2020
BUY
$10.89 - $21.47 $972,683 - $1.92 Million
89,319 Added 80.43%
200,364 $2.95 Million
Q1 2020

May 04, 2020
SELL
$10.23 - $24.56 $22,506 - $54,032
-2,200 Reduced 1.94%
111,045 $1.3 Million
Q4 2019

Jan 31, 2020
BUY
$17.42 - $26.61 $34,491 - $52,687
1,980 Added 1.78%
113,245 $2.66 Million
Q3 2019

Oct 24, 2019
BUY
$16.36 - $21.39 $26,176 - $34,224
1,600 Added 1.46%
111,265 $2.06 Million
Q2 2019

Aug 02, 2019
BUY
$16.93 - $26.22 $995,314 - $1.54 Million
58,790 Added 115.56%
109,665 $1.95 Million
Q1 2019

Apr 18, 2019
BUY
$23.15 - $28.34 $99,545 - $121,862
4,300 Added 9.23%
50,875 $1.24 Million
Q4 2018

Feb 06, 2019
BUY
$22.03 - $32.01 $250,040 - $363,313
11,350 Added 32.22%
46,575 $1.21 Million
Q3 2018

Oct 29, 2018
SELL
$30.0 - $40.85 $3,000 - $4,085
-100 Reduced 0.28%
35,225 $1.12 Million
Q2 2018

Aug 06, 2018
SELL
$26.4 - $42.0 $102,960 - $163,800
-3,900 Reduced 9.94%
35,325 $1.37 Million
Q1 2018

Apr 17, 2018
SELL
$18.43 - $28.8 $136,382 - $213,120
-7,400 Reduced 15.87%
39,225 $1.08 Million
Q4 2017

Feb 13, 2018
BUY
$14.8 - $18.85 $690,050 - $878,881
46,625
46,625 $844,000

Others Institutions Holding HRTX

# of Institutions
182
Shares Held
125M
Call Options Held
847K
Put Options Held
47.7K
View Full List

About HERON THERAPEUTICS, INC.

HRTX Quotes by TradingView
  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $226M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Congress Park Capital LLC Portfolio

Follow Congress Park Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Congress Park Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email